|
1
|
World Health Organization: Cancer Today.
Gco.iarc.fr. 2022. International Agency for Research
on Cancer. https://gco.iarc.fr/today/home.
|
|
2
|
Ghosh A, Wang X, Klein E and Heston WDW:
Novel role of prostate-specific membrane antigen in suppressing
prostate cancer invasiveness. Cancer Res. 65:727–731.
2005.PubMed/NCBI
|
|
3
|
EAU Guidelines. EAU Annual Congress
Amsterdam 2022. ISBN 978-94-92671-16-5.
|
|
4
|
Trabulsi EJ, Rumble RB, Jadvar H, Hope T,
Pomper M, Turkbey B, Rosenkrantz AB, Verma S, Margolis DJ,
Froemming A, et al: Optimum imaging strategies for advanced
prostate cancer: ASCO guideline. J Clin Oncol. 38:1963–1996.
2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Parker C, Castro E, Fizazi K, Heidenreich
A, Ost P, Procopio G, Tombal B and Gillessen S: ESMO Guidelines
Committee. Electronic address: simpleclinicalguidelines@esmo.org.
Prostate cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 31:1119–1134. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lowrance WT, Breau RH, Chou R, Chapin BF,
Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK,
et al: Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. J
Urol. 205:14–21. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ahmed HU, El-Shater Bosaily A, Brown LC,
Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG,
Freeman A, et al: Diagnostic accuracy of multi-parametric MRI and
TRUS biopsy in prostate cancer (PROMIS): A paired validating
confirmatory study. Lancet. 389:815–822. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Somford DM, Hamoen EH, Fütterer JJ, van
Basten JP, Hulsbergen-van de Kaa CA, Vreuls W, van Oort IM,
Vergunst H, Kiemeney LA, Barentsz JO and Witjes JA: The predictive
value of endorectal 3 Tesla multiparametric magnetic resonance
imaging for extraprostatic extension in patients with low,
intermediate and high risk prostate cancer. J Urol. 190:1728–1734.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kalapara AA, Nzenza T, Pan HYC, Ballok Z,
Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, et
al: Detection and localisation of primary prostate cancer using
68gallium prostate-specific membrane antigen positron
emission tomography/computed tomography compared with
multiparametric magnetic resonance imaging and radical
prostatectomy specimen pathology. BJU Int. 126:83–90.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Peng L, Li J, Meng C, Li J, You C, Tang D,
Wei T, Xiong W and Li Y: Can 68Ga-prostate specific
membrane antigen positron emission tomography/computerized
tomography provide an accurate lymph node staging for patients with
medium/high risk prostate cancer? A diagnostic meta-analysis.
Radiat Oncol. 15(227)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wu H, Xu T, Wang X, Yu YB, Fan ZY, Li DX,
Luo L, Yang XC, Jiao W and Niu HT: Diagnostic performance of
68gallium labelled prostate-specific membrane antigen
positron emission tomography/computed tomography and magnetic
resonance imaging for staging the prostate cancer with intermediate
or high risk prior to radical prostatectomy: A systematic review
and meta-analysis. World J Mens Health. 38:208–219. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Herlemann A, Wenter V, Kretschmer A,
Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG,
Gratzke C and Fendler WP: 68Ga-PSMA positron emission
tomography/computed tomography provides accurate staging of lymph
node regions prior to lymph node dissection in patients with
prostate cancer. Eur Urol. 70:553–557. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hope TA, Eiber M, Armstrong WR, Juarez R,
Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, et
al: Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal
metastasis detection prior to radical prostatectomy and pelvic
lymph node dissection: A multicenter prospective phase 3 imaging
trial. JAMA Oncol. 7:1635–1642. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yaxley JW, Raveenthiran S, Nouhaud FX,
Samartunga H, Yaxley AJ, Coughlin G, Delahunt B, Egevad L, McEwan L
and Wong D: Outcomes of primary lymph node staging of intermediate
and high risk prostate cancer with 68Ga-PSMA positron
emission tomography/computerized tomography compared to
histological correlation of pelvic lymph node pathology. J Urol.
201:815–820. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
van Kalmthout LWM, van Melick HHE,
Lavalaye J, Meijer RP, Kooistra A, de Klerk JMH, Braat AJAT,
Kaldeway HP, de Bruin PC, de Keizer B and Lam MGEH: Prospective
validation of gallium-68 prostate specific membrane
antigen-positron emission tomography/computerized tomography for
primary staging of prostate cancer. J Urol. 203:537–545.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hofman MS, Lawrentschuk N, Francis RJ,
Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M,
Shakher R, et al: Prostate-specific membrane antigen PET-CT in
patients with high-risk prostate cancer before curative-intent
surgery or radiotherapy (proPSMA): A prospective, randomised,
multicentre study. Lancet. 395:1208–1216. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chakraborty PS, Kumar R, Tripathi M, Das
CJ and Bal C: Detection of brain metastasis with 68Ga-labeled PSMA
ligand PET/CT: A novel radiotracer for imaging of prostate
carcinoma. Clin Nucl Med. 40:328–329. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Calais J, Zhu S, Hirmas N, Eiber M,
Hadaschik B, Stuschke M, Herrmann K, Czernin J, Kishan AU, Nickols
NG, et al: Phase 3 multicenter randomized trial of PSMA PET/CT
prior to definitive radiation therapy for unfavorable
intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study
protocol. BMC Cancer. 21(512)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Calais J, Zhu S, Hirmas N, Eiber M,
Hadaschik BA, Stuschke M, Herrmann K, Czernin J, Kishan AU, Nickols
NG, et al: Phase III randomized trial of PSMA PET prior to
definitive radiation therapy for unfavorable intermediate-risk or
high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245. J
Clin Oncol. 39 (Suppl 6)(TPS172)2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Calais J, Kishan AU, Cao M, Fendler WP,
Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, et al:
Potential impact of 68Ga-PSMA-11 PET/CT on the planning
of definitive radiation therapy for prostate cancer. J Nucl Med.
59:1714–1721. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sonni I, Eiber M, Fendler WP, Alano RM,
Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J
and Calais J: Impact of 68Ga-PSMA-11 PET/CT on staging
and management of prostate cancer patients in various clinical
settings: A prospective single-center study. J Nucl Med.
61:1153–1160. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Phillips R, Shi WY, Deek M, Radwan N, Lim
SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, et al:
Outcomes of observation vs. stereotactic ablative radiation for
oligometastatic prostate cancer: The ORIOLE phase 2 randomized
clinical trial. JAMA Oncol. 6:650–659. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Maurer T, Gschwend JE, Rauscher I,
Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H,
Beer AJ, et al: Diagnostic efficacy of (68)gallium-PSMA positron
emission tomography compared to conventional imaging for lymph node
staging of 130 consecutive patients with intermediate to high risk
prostate cancer. J Urol. 195:1436–1443. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zarbiv Y, Peerless Y, Wygoda M, Orevi M,
Meir K, Gofrit ON, Yutkin V and Frank S: Real-world Israeli single
institution experience with PET-PSMA for staging of patients with
clinically staged localized prostate carcinoma. Cancer Rep
(Hoboken). 4(e1386)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Onal C, Torun N, Oymak E, Guler OC, Reyhan
M and Yapar AF: Retrospective correlation of 68ga-psma
uptake with clinical parameters in prostate cancer patients
undergoing definitive radiotherapy. Ann Nucl Med. 34:388–396.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Uprimny C, Kroiss AS, Decristoforo C,
Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig
LG, Maffey-Steffan J, et al: 68Ga-PSMA-11 PET/CT in
primary staging of prostate cancer: PSA and gleason score predict
the intensity of tracer accumulation in the primary tumour. Eur J
Nucl Med Mol Imaging. 44:941–949. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş
MG and Çermik TF: 68Ga-PSMA-11 PET/CT in newly diagnosed prostate
adenocarcinoma. Clin Nucl Med. 43:e422–e427. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Amiel T, Würnschimmel C, Heck M, Horn T,
Nguyen N, Budäus L, Knipper S, Wenzel M, Rauscher I, Eiber M, et
al: Regional lymph node metastasis on prostate specific membrane
antigen positron emission tomography correlates with decreased
biochemical recurrence-free and therapy-free survival after radical
prostatectomy: A retrospective single-center single-arm
observational study. J Urol. 205:1663–1670. 2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hotta M, Gafita A, Czernin J and Calais J:
Outcome of patients with PSMA PET/CT screen failure by VISION
criteria and treated with 177Lu-PSMA therapy: A
multicenter retrospective analysis. J Nucl Med. 63:1484–1488.
2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Seifert R, Seitzer K, Herrmann K, Kessel
K, Schäfers M, Kleesiek J, Weckesser M, Boegemann M and Rahbar K:
Analysis of PSMA expression and outcome in patients with advanced
prostate cancer receiving 177Lu-PSMA-617 radioligand
therapy. Theranostics. 10:7812–7820. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Afshar-Oromieh A, Zechmann CM, Malcher A,
Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA,
Giesel FL, Debus J and Haberkorn U: Comparison of PET imaging with
a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for
the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol
Imaging. 41:11–20. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Morigi JJ, Stricker PD, van Leeuwen PJ,
Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A,
et al: Prospective comparison of 18F-fluoromethylcholine versus
68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA
after curative treatment and are being considered for targeted
therapy. J Nucl Med. 56:1185–1190. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Hope TA, Goodman JZ, Allen IE, Calais J,
Fendler WP and Carroll PR: Metaanalysis of 68Ga-PSMA-11
PET accuracy for the detection of prostate cancer validated by
histopathology. J Nucl Med. 60:786–793. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
McCarthy M, Francis R, Tang C, Watts J and
Campbell A: A multicenter prospective clinical trial of
68gallium PSMA HBED-CC PET-CT restaging in biochemically
relapsed prostate carcinoma: Oligometastatic rate and distribution
compared with standard imaging. Int J Radiat Oncol Biol Phys.
104:801–808. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Fendler WP, Calais J, Eiber M, Flavell RR,
Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, et
al: Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent
prostate cancer: A prospective single-arm clinical trial. JAMA
Oncol. 5:856–863. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hofman MS, Hicks RJ, Maurer T and Eiber M:
Prostate-specific membrane antigen PET: Clinical utility in
prostate cancer, normal patterns, pearls, and pitfalls.
Radiographics. 38:200–217. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Rischpler C, Beck TI, Okamoto S, Schlitter
AM, Knorr K, Schwaiger M, Gschwend J, Maurer T, Meyer PT and Eiber
M: 68Ga-PSMA-HBED-CC uptake in cervical, celiac, and
sacral ganglia as an important pitfall in prostate cancer PET
imaging. J Nucl Med. 59:1406–1411. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Fendler WP, Ferdinandus J, Czernin J,
Eiber M, Flavell RR, Behr SC, Wu IK, Lawhn-Heath C, Pampaloni MH,
Reiter RE, et al: Impact of 68Ga-PSMA-11 PET on the
management of recurrent prostate cancer in a prospective single-arm
clinical trial. J Nucl Med. 61:1793–1799. 2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Calais J, Fendler WP, Eiber M, Gartmann J,
Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, et
al: Impact of 68Ga-PSMA-11 PET/CT on the management of
prostate cancer patients with biochemical recurrence. J Nucl Med.
59:434–441. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Rousseau C, Le Thiec M, Ferrer L, Rusu D,
Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis
A, et al: Preliminary results of a 68Ga-PSMA PET/CT
prospective study in prostate cancer patients with occult
recurrence: Diagnostic performance and impact on therapeutic
decision-making. Prostate. 79:1514–1522. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Calais J, Czernin J, Fendler WP, Elashoff
D and Nickols NG: Randomized prospective phase III trial of
68Ga-PSMA-11 PET/CT molecular imaging for prostate
cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer.
19(18)2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kratochwil C, Giesel FL, Eder M,
Afshar-Oromieh A, Benešová M, Mier W, Kopka K and Haberkorn U:
[77Lu] Lutetium-labelled PSMA ligand-induced remission
in a patient with metastatic prostate cancer. Eur J Nucl Med Mol
Imaging. 42:987–988. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Rahbar K, Ahmadzadehfar H, Kratochwil C,
Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M,
Drzezga A, et al: German multicenter study investigating
177Lu-PSMA-617 radioligand therapy in advanced prostate cancer
patients. J Nucl Med. 58:85–90. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Heck MM, Tauber R, Schwaiger S, Retz M,
D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber
WA, et al: Treatment outcome, toxicity, and predictive factors for
radioligand therapy with 177Lu-PSMA-I&T in
metastatic castration-resistant prostate cancer. Eur Urol.
75:920–926. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Hofman MS, Violet J, Hicks RJ, Ferdinandus
J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG,
et al: [177Lu]-PSMA-617 radionuclide treatment in
patients with metastatic castration-resistant prostate cancer
(LuPSMA trial): A single-centre, single-arm, phase 2 study. Lancet
Oncol. 19:825–833. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Violet J, Sandhu S, Iravani A, Ferdinandus
J, Thang SP, Kong G, Kumar AR, Akhurst T, Pattison DA, Beaulieu A,
et al: Long-term follow-up and outcomes of retreatment in an
expanded 50-patient single-center phase II prospective trial of
177Lu-PSMA-617 theranostics in metastatic
castration-resistant prostate cancer. J Nucl Med. 61:857–865.
2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Hofman MS, Emmett L, Sandhu S, Iravani A,
Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, et al:
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with
metastatic castration-resistant prostate cancer (TheraP): A
randomised, open-label, phase 2 trial. Lancet. 397:797–804.
2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Sartor O, de Bono J, Chi KN, Fizazi K,
Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N,
El-Haddad G, et al: Lutetium-177-PSMA-617 for metastatic
castration-resistant prostate cancer. N Engl J Med. 385:1091–1103.
2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Khreish F, Ghazal Z, Marlowe RJ, Rosar F,
Sabet A, Maus S, Linxweiler J, Bartholomä M and Ezziddin S: 177
Lu-PSMA-617 radioligand therapy of metastatic castration-resistant
prostate cancer: Initial 254-patient results from a prospective
registry (REALITY study). Eur J Nucl Med Mol Imaging. 49:1075–1085.
2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Privé BM, Janssen MJR, van Oort IM,
Muselaers CHJ, Jonker MA, van Gemert WA, de Groot M, Westdorp H,
Mehra N, Verzijlbergen JF, et al: Update to a randomized controlled
trial of lutetium-177-PSMA in oligo-metastatic hormone-sensitive
prostate cancer: The BULLSEYE trial. Trials. 22(768)2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Erdogan M, Sengul SS, Cetin B, Avcı M,
Yagci S, Ozkoç I, Barikan DE and Yildiz M: The role of
Ga68 PSMA PET/CT imaging in Lu177 PSMA
treatment planning in metastatic castration-resistant prostate
cancer. Ann Nucl Med. 36:562–569. 2022.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Peters SMB, Hofferber R, Privé BM, de
Bakker M, Gotthardt M, Janssen M, de Lange F, Muselaers CHJ, Mehra
N, Witjes JA, et al: [68Ga]Ga-PSMA-11 PET imaging as a
predictor for absorbed doses in organs at risk and small lesions in
[177Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol
Imaging. 49:1101–1112. 2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Paschalis A, Sheehan B, Riisnaes R,
Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G,
Yuan W, et al: Prostate-specific membrane antigen heterogeneity and
DNA repair defects in prostate cancer. Eur Urol. 76:469–478.
2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Lückerath K, Wei L, Fendler WP,
Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig
M, Reiter RE, et al: Preclinical evaluation of PSMA expression in
response to androgen receptor blockade for theranostics in prostate
cancer. EJNMMI Res. 8(96)2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Rosar F, Dewes S, Ries M, Schaefer A,
Khreish F, Maus S, Bohnenberger H, Linxweiler J, Bartholomä M,
Ohlmann C and Ezziddin S: New insights in the paradigm of
upregulation of tumoral PSMA expression by androgen receptor
blockade: Enzalutamide induces PSMA upregulation in
castration-resistant prostate cancer even in patients having
previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging.
47:687–694. 2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Grignon DJ, Caplan R, Sarkar FH, Lawton
CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA,
et al: p53 status and prognosis of locally advanced prostatic
adenocarcinoma: A study based on RTOG 8610. J Natl Cancer Inst.
89:158–165. 1997.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Stuparu AD, Capri JR, Meyer CAL, Le TM,
Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais
J, et al: Mechanisms of resistance to prostate-specific membrane
antigen-targeted radioligand therapy in a mouse model of prostate
cancer. J Nucl Med. 62:989–995. 2021.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Nadal R, Schweizer M, Kryvenko ON, Epstein
JI and Eisenberger MA: Small cell carcinoma of the prostate. Nat
Rev Urol. 11:213–219. 2014.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Parghane R and Basu S: Small cell
transformation of metastatic prostate adenocarcinoma diagnosed by
dual-tracer PET/CT (68Ga-PSMA and 18F-FDG):
Potential clinical utility in therapeutic decision making and
treatment monitoring. J Nucl Med Technol. 47:85–87. 2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Hope TA, Truillet C, Ehman EC,
Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ and
Evans MJ: 68Ga-PSMA-11 PET imaging of response to androgen receptor
inhibition: First human experience. J Nucl Med. 58:81–84.
2017.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Schuster DM: SPOTLIGHT Study Group.
Detection rate of 18F-rhPSMA-7.3 PET in patients with
suspected prostate cancer recurrence: Results from a phase 3,
prospective, multicenter study (SPOTLIGHT). J Clin Oncol. 40
(Suppl)(S9)2022.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Pienta KJ, Gorin MA, Rowe SP, Carroll PR,
Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A,
et al: A phase 2/3 prospective multicenter study of the diagnostic
accuracy of prostate specific membrane antigen PET/CT with
18F-DCFPyL in prostate cancer patients (OSPREY). J Urol.
206:52–61. 2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Morris MJ, Rowe SP, Gorin MA, Saperstein
L, Pouliot F, Josephson D, Wong JYC, Pantel AR, Cho SY, Gage KL, et
al: Diagnostic performance of 18F-DCFPyL-PET/CT in men
with biochemically recurrent prostate cancer: Results from the
CONDOR phase III, multicenter study. Clin Cancer Res. 27:3674–3682.
2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Olivier P, Giraudet AL, Skanjeti A, Merlin
C, Weinmann P, Rudolph I, Hoepping A and Gauthé M: Phase III study
of 18F-PSMA-1007 versus 18F-fluorocholine
PET/CT for localization of prostate cancer biochemical recurrence:
A prospective, randomized, cross-over, multicenter study. J Nucl
Med: Nov 23, 2022 (Epub ahead of print).
|
|
65
|
Hoffmann MA, Müller-Hübenthal J, Rosar F,
Fischer N, von Eyben FE, Buchholz HG, Wieler HJ and Schreckenberger
M: Primary staging of prostate cancer patients with
[18F]PSMA-1007 PET/CT compared with
[68Ga]Ga-PSMA-11 PET/CT. J Clin Med.
11(5064)2022.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Müller C, Umbricht CA, Gracheva N, Tschan
VJ, Pellegrini G, Bernhardt P, Zeevaart JR, Köster U, Schibli R and
van der Meulen NP: Terbium-161 for PSMA-targeted radionuclide
therapy of prostate cancer. Eur J Nucl Med Mol Imaging.
46:1919–1930. 2019.PubMed/NCBI View Article : Google Scholar
|
